Delaware
|
30-0781441
|
(State or other jurisdiction of incorporation or organization)
|
(IRS Employer Identification No.)
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☐ (Do not check if a smaller reporting company)
|
Smaller reporting company ☒
|
Emerging growth company ☐
|
|
Page
|
|
|
Consolidated Balance Sheets as of September 30, 2018 and March 31, 2018 (Unaudited)
|
F1
|
|
|
Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended September 30, 2018 and 2017 (Unaudited)
|
F2
|
|
|
Consolidated Statements of Cash Flows for the Six Months Ended September 30, 2018 and 2017 (Unaudited)
|
F3
|
|
|
Notes to Consolidated Financial Statements (Unaudited)
|
F4-F8
|
SEPTEMBER 30,
|
MARCH 31,
|
|||||||
2018
|
2018
|
|||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
31,948,886
|
$
|
25,353,360
|
||||
Accounts receivable
|
122,093
|
174,558
|
||||||
Inventories
|
1,947,262
|
2,383,382
|
||||||
Purchase deposit to related party
|
1,286,166
|
1,412,864
|
||||||
Prepaid leases – current portion
|
856,662
|
741,583
|
||||||
Total current assets
|
36,161,069
|
30,065,747
|
||||||
|
||||||||
Prepaid leases
|
1,319,382
|
641,349
|
||||||
Development cost of acer truncatum bunge planting
|
45,459,621
|
48,984,881
|
||||||
Plant, property, and equipment, net
|
14,761,960
|
16,793,413
|
||||||
Intangible assets, net
|
10,225,176
|
11,862,017
|
||||||
Deferred tax assets
|
182,405
|
200,387
|
||||||
Security deposit to related party
|
1,453,657
|
1,590,305
|
||||||
Total assets
|
$
|
109,563,270
|
$
|
110,138,099
|
||||
|
||||||||
Liabilities and Stockholders' Equity
|
||||||||
|
||||||||
Current liabilities:
|
||||||||
Accounts payable and other accrued expenses
|
$
|
107,582
|
$
|
372,782
|
||||
Advance from customers
|
-
|
445,829
|
||||||
Taxes payable
|
2,089,423
|
1,164,198
|
||||||
Total current liabilities
|
2,197,005
|
1,982,809
|
||||||
|
||||||||
Stockholders' Equity
|
||||||||
Preferred stock, par value $0.001 per share; 5,000,000 shares authorized, zero shares issued and outstanding
|
-
|
-
|
||||||
12% Preferred stock, par value $500 per share; 45 shares authorized, issued and outstanding
|
22,500
|
22,500
|
||||||
Common stock, par value $0.001 per share; 100,000,000 shares authorized; 29,839,168 and 29,789,168 shares issued and outstanding at September 30, 2018 and March 31, 2018, respectively
|
29,839
|
29,789
|
||||||
Additional paid-in capital
|
4,363,788
|
4,322,838
|
||||||
Statutory reserve
|
1,828,504
|
1,828,504
|
||||||
Retained earnings
|
103,015,416
|
94,447,937
|
||||||
Accumulated other comprehensive income (loss)
|
(4,917,587
|
)
|
4,455,017
|
|||||
Total stockholders' equity attributable to the Company
|
104,342,460
|
105,106,585
|
||||||
Noncontrolling interest
|
3,023,805
|
3,048,705
|
||||||
Total stockholders' equity
|
107,366,265
|
108,155,290
|
||||||
Total liabilities and stockholders' equity
|
$
|
109,563,270
|
$
|
110,138,099
|
THREE MONTHS ENDED
|
SIX MONTHS ENDED
|
|||||||||||||||
SEPTEMBER 30,
|
SEPTEMBER 30,
|
|||||||||||||||
2018
|
2017
|
2018
|
2017
|
|||||||||||||
Sales
|
$
|
18,684,939
|
$
|
13,866,784
|
$
|
39,573,786
|
$
|
31,001,649
|
||||||||
Cost of Goods Sold (including $3,785,996 and $3,020,708 from a related party for the three months ended September 30, 2018 and 2017, respectively; including $8,176,320 and $7,309,643 from a related party for the six months ended September 30, 2018 and 2017, respectively)
|
10,619,845
|
8,811,390
|
22,584,545
|
19,098,538
|
||||||||||||
Gross profit
|
8,065,094
|
5,055,394
|
16,989,241
|
11,903,111
|
||||||||||||
Operating expenses
|
||||||||||||||||
Selling expenses
|
1,312,878
|
1,082,147
|
2,704,481
|
2,318,439
|
||||||||||||
General and administrative expenses
|
1,110,995
|
868,258
|
2,192,044
|
1,776,663
|
||||||||||||
Research and development expenses
|
68,424
|
62,033
|
391,157
|
126,411
|
||||||||||||
Total operating expenses
|
2,492,297
|
2,012,438
|
5,287,682
|
4,221,513
|
||||||||||||
Income from operations
|
5,572,797
|
3,042,956
|
11,701,559
|
7,681,598
|
||||||||||||
Gain on disposal of acer truncatum bunge plants
|
-
|
-
|
-
|
573,092
|
||||||||||||
Interest income
|
34,972
|
31,199
|
75,045
|
56,302
|
||||||||||||
Income before income tax provision
|
5,607,769
|
3,074,155
|
11,776,604
|
8,310,992
|
||||||||||||
Income tax provision
|
1,401,942
|
768,539
|
2,944,151
|
2,077,748
|
||||||||||||
Net income
|
4,205,827
|
2,305,616
|
8,832,453
|
6,233,244
|
||||||||||||
Less: Net income attributable to noncontrolling interest
|
126,175
|
69,168
|
264,974
|
186,997
|
||||||||||||
Net income attributable to the Company
|
4,079,652
|
2,236,448
|
8,567,479
|
6,046,247
|
||||||||||||
Other comprehensive income (loss):
|
||||||||||||||||
Foreign currency translation adjustment
|
(4,125,116
|
)
|
1,908,799
|
(9,662,478
|
)
|
3,564,300
|
||||||||||
Comprehensive income (loss)
|
80,711
|
4,214,415
|
(830,025
|
)
|
9,797,544
|
|||||||||||
Less: Comprehensive income (loss) attributable to noncontrolling interest
|
2,422
|
126,432
|
(24,900
|
)
|
292,747
|
|||||||||||
Comprehensive income (loss) attributable to the Company
|
$
|
78,289
|
$
|
4,087,983
|
$
|
(805,125
|
)
|
$
|
9,504,797
|
|||||||
|
||||||||||||||||
Earnings per common share
|
||||||||||||||||
Basic and Diluted
|
$
|
0.14
|
$
|
0.08
|
$
|
0.29
|
$
|
0.20
|
||||||||
|
||||||||||||||||
Weighted average number of common shares outstanding
|
||||||||||||||||
Basic and Diluted
|
29,839,168
|
29,789,168
|
29,821,682
|
29,789,168
|
SIX MONTHS ENDED
|
||||||||
SEPTEMBER 30,
|
||||||||
2018
|
2017
|
|||||||
Cash Flows From Operating Activities:
|
||||||||
Net income
|
$
|
8,832,453
|
$
|
6,233,244
|
||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
Depreciation and amortization of plant, property and equipment
|
682,403
|
615,112
|
||||||
Amortization of intangible assets
|
644,301
|
628,768
|
||||||
Amortization of prepaid leases
|
446,857
|
431,644
|
||||||
Stock-based compensation expenses
|
41,000
|
-
|
||||||
Deferred taxes
|
797
|
278,054
|
||||||
Gain on disposal of acer truncatum bunge plants
|
-
|
(573,092
|
)
|
|||||
Changes in operating assets and liabilities:
|
||||||||
Purchase deposit to vendors
|
-
|
664,506
|
||||||
Inventory
|
241,332
|
3,230,636
|
||||||
Accounts receivable
|
39,087
|
1,158,886
|
||||||
Cash received from cancellation of lease
|
-
|
56,732
|
||||||
Prepaid expenses
|
-
|
(279,239
|
)
|
|||||
Prepaid leases
|
(1,398,241
|
)
|
-
|
|||||
Taxes payable
|
1,069,603
|
(1,155,471
|
)
|
|||||
Purchase deposit and accounts payable to related party, net
|
5,526
|
(686,806
|
)
|
|||||
Accounts payable and other accrued expenses
|
(243,253
|
)
|
24,034
|
|||||
Advance from customers
|
(425,147
|
)
|
113,615
|
|||||
Net cash provided by operating activities
|
9,936,718
|
10,740,623
|
||||||
|
||||||||
Cash Flows From Investing Activities:
|
||||||||
Acquisition of property, plant and equipment
|
(68,483
|
)
|
(2,110,189
|
)
|
||||
Proceeds from disposal of acer truncatum bunge plants
|
-
|
2,114,541
|
||||||
Development cost of acer truncatum bunge planting
|
(713,375
|
)
|
(2,420,741
|
)
|
||||
Net cash used in investing activities
|
(781,858
|
)
|
(2,416,389
|
)
|
||||
|
||||||||
Effect of exchange rate changes on cash and cash equivalents
|
(2,559,334
|
)
|
558,074
|
|||||
Net increase in cash and cash equivalents
|
6,595,526
|
8,882,308
|
||||||
Cash and cash equivalents at beginning of period
|
25,353,360
|
10,308,622
|
||||||
Cash and cash equivalents at end of period
|
$
|
31,948,886
|
$
|
19,190,930
|
||||
Supplemental disclosures of cash flow information:
|
||||||||
Cash paid during the periods for:
|
||||||||
Interest
|
$
|
-
|
$
|
-
|
||||
Income taxes
|
$
|
1,966,462
|
$
|
2,790,002
|
September 30
|
September 30
|
|||||||
2018
|
2017
|
|||||||
Period End Exchange Rate (RMB/USD)
|
6.8792
|
6.6369
|
||||||
Average Period Exchange Rate (RMB/USD)
|
6.5940
|
6.7569
|
September 30,
|
March 31,
|
|||||||
|
2018
|
2018
|
||||||
Raw materials
|
$
|
786,007
|
$
|
233,138
|
||||
Packaging materials
|
190,477
|
652,179
|
||||||
Work-in-process
|
152,051
|
686,234
|
||||||
Finished goods
|
818,727
|
811,831
|
||||||
Total Inventories
|
$
|
1,947,262
|
$
|
2,383,382
|
September 30,
|
March 31,
|
|||||||
|
2018
|
2018
|
||||||
Machinery and equipment
|
$
|
3,285,970
|
$
|
3,594,861
|
||||
Office equipment and automobiles
|
769,106
|
769,589
|
||||||
Building
|
12,437,555
|
13,606,722
|
||||||
Leasehold improvements
|
3,876,194
|
4,240,568
|
||||||
Subtotal
|
20,368,825
|
22,211,740
|
||||||
Less: Accumulated depreciation and amortization
|
(5,606,865
|
)
|
(5,418,327
|
)
|
||||
Total plant, property and equipment, net
|
$
|
14,761,960
|
$
|
16,793,413
|
September 30,
|
March 31,
|
|||||||
2018
|
2018
|
|||||||
Corporate income tax - foreign
|
$
|
1,411,597
|
$
|
519,875
|
||||
Value-added tax - foreign
|
610,034
|
580,429
|
||||||
Other tax and fees - foreign
|
67,792
|
63,894
|
||||||
Total tax payable
|
$
|
2,089,423
|
$
|
1,164,198
|
Six Months Ended
|
||||||||
September 30,
|
||||||||
2018
|
2017
|
|||||||
21% | 35% | |||||||
Tax at U.S. statutory rate
|
$
|
2,473,087
|
$
|
2,908,847
|
||||
Tax rate difference between China and U.S.
|
471,064
|
(831,099
|
)
|
|||||
Effective tax
|
$
|
2,944,151
|
$
|
2,077,748
|
Six Months Ended
|
||||||||
September 30,
|
||||||||
2018
|
2017
|
|||||||
Current
|
$
|
2,943,354
|
$
|
1,799,694
|
||||
Deferred
|
797
|
278,054
|
||||||
Total
|
$
|
2,944,151
|
$
|
2,077,748
|
Three Months Ended
|
||||||||||||||||
September 30,
|
$ |
%
|
||||||||||||||
2018
|
2017
|
Change
|
Change
|
|||||||||||||
Sales
|
18,684,939
|
13,866,784
|
4,818,155
|
34.7
|
%
|
|||||||||||
Cost of Goods sold
|
10,619,845
|
8,811,390
|
1,808,455
|
20.5
|
%
|
|||||||||||
Gross Profit
|
8,065,094
|
5,055,394
|
3,009,700
|
59.5
|
%
|
|||||||||||
Operating Expenses
|
2,492,297
|
2,012,438
|
479,859
|
23.8
|
%
|
|||||||||||
Operating Income
|
5,572,797
|
3,042,956
|
2,529,841
|
83.1
|
%
|
|||||||||||
Interest Income
|
34,972
|
31,199
|
3,773
|
12.1
|
%
|
|||||||||||
Income Tax Provision
|
1,401,942
|
768,539
|
633,403
|
82.4
|
%
|
|||||||||||
Net Income
|
4,205,827
|
2,305,616
|
1,900,211
|
82.4
|
%
|
|||||||||||
Comprehensive Income
|
80,711
|
4,214,415
|
(4,133,704
|
)
|
(98.1
|
)%
|
Six Months Ended
|
||||||||||||||||
September 30,
|
$ |
%
|
||||||||||||||
2018
|
2017
|
Change
|
Change
|
|||||||||||||
Sales
|
39,573,786
|
31,001,649
|
8,572,137
|
27.7
|
%
|
|||||||||||
Cost of Goods sold
|
22,584,545
|
19,098,538
|
3,486,007
|
18.3
|
%
|
|||||||||||
Gross Profit
|
16,989,241
|
11,903,111
|
5,086,130
|
42.7
|
%
|
|||||||||||
Operating Expenses
|
5,287,682
|
4,221,513
|
1,066,169
|
25.3
|
%
|
|||||||||||
Operating Income
|
11,701,559
|
7,681,598
|
4,019,961
|
52.3
|
%
|
|||||||||||
Interest Income
|
75,045
|
56,302
|
18,743
|
33.3
|
%
|
|||||||||||
Gain on Disposal of Acer Truncatum Bunge Plants
|
-
|
573,092
|
(573,092
|
)
|
(100.0
|
)%
|
||||||||||
Income Tax Provision
|
2,944,151
|
2,077,748
|
866,403
|
41.7
|
%
|
|||||||||||
Net Income
|
8,832,453
|
6,233,244
|
2,599,209
|
41.7
|
%
|
|||||||||||
Comprehensive Income (Loss)
|
(830,025
|
)
|
9,797,544
|
(10,627,569
|
)
|
(108.5
|
)%
|
For the Three Months
Ended September 30,
|
||||||||||||||||
2018
|
2017
|
|||||||||||||||
Health care supplements
|
6,918,146
|
37.0
|
%
|
5,519,198
|
39.8
|
%
|
||||||||||
Drugs (Huoliyuan capsule)
|
7,067,046
|
37.8
|
%
|
6,856,369
|
49.4
|
%
|
||||||||||
Acer truncatum oil
|
4,699,747
|
25.2
|
%
|
1,491,217
|
10.8
|
%
|
||||||||||
Total
|
18,684,939
|
100.0
|
%
|
13,866,784
|
100.0
|
%
|
For the Six Months
Ended September 30,
|
||||||||||||||||
2018
|
2017
|
|||||||||||||||
Health care supplements
|
14,928,744
|
37.7
|
%
|
13,364,199
|
43.1
|
%
|
||||||||||
Drugs (Huoliyuan capsule)
|
14,697,336
|
37.1
|
%
|
13,251,411
|
42.7
|
%
|
||||||||||
Acer truncatum oil
|
9,947,706
|
25.2
|
%
|
4,386,039
|
14.2
|
%
|
||||||||||
Total
|
39,573,786
|
100.1
|
%
|
31,001,649
|
100.1
|
%
|
September 30,
2018 |
Gross
Profit Margin |
September 30,
2017 |
Gross
Profit Margin |
Change
in $ |
Variance
|
|||||||||||||||||||
Health care supplements
|
3,066,425
|
44.3
|
%
|
2,456,533
|
44.5
|
%
|
609,892
|
24.8
|
%
|
|||||||||||||||
Drugs (Huoliyuan capsule)
|
2,131,152
|
30.2
|
%
|
1,970,445
|
28.7
|
%
|
160,707
|
8.2
|
%
|
|||||||||||||||
Acer truncatum oil
|
2,867,517
|
61.0
|
%
|
628,416
|
42.1
|
%
|
2,239,101
|
356.3
|
%
|
|||||||||||||||
Total
|
8,065,094
|
43.2
|
%
|
5,055,394
|
36.5
|
%
|
3,009,700
|
59.5
|
%
|
September 30,
2018 |
Gross
Profit Margin |
September 30,
2017 |
Gross
Profit Margin |
Change
in $ |
Variance
|
|||||||||||||||||||
Health care supplements
|
6,623,716
|
44.4
|
%
|
5,964,647
|
44.6
|
%
|
659,069
|
11.0
|
%
|
|||||||||||||||
Drugs (Huoliyuan capsule)
|
4,324,819
|
29.4
|
%
|
4,022,212
|
30.4
|
%
|
302,607
|
7.5
|
%
|
|||||||||||||||
Acer truncatum oil
|
6,040,706
|
60.7
|
%
|
1,916,252
|
43.7
|
%
|
4,124,454
|
215.2
|
%
|
|||||||||||||||
Total
|
16,989,241
|
42.9
|
%
|
11,903,111
|
38.4
|
%
|
5,086,130
|
42.7
|
%
|
For the Six Months Ended September 30,
|
||||||||||||||||
2018
|
2017
|
Change in $
|
Change in %
|
|||||||||||||
Net cash provided by operating activities
|
$
|
9,936,718
|
$
|
10,740,623
|
(803,905
|
)
|
(7.5
|
)%
|
||||||||
Net cash used in investing activities
|
$
|
(781,858
|
)
|
$
|
(2,416,389
|
)
|
1,634,531
|
(67.6
|
)%
|
|||||||
Effect of exchange rate change on cash and cash equivalents
|
$
|
(2,559,334
|
)
|
$
|
558,074
|
(3,117,408
|
)
|
(558.6
|
)%
|
|||||||
Net increase in cash and cash equivalents
|
$
|
6,595,526
|
$
|
8,882,308
|
(2,286,782
|
)
|
(25.7
|
)%
|
||||||||
Cash and cash equivalents, beginning balance
|
$
|
25,353,360
|
$
|
10,308,622
|
15,044,738
|
145.9
|
%
|
|||||||||
Cash and cash equivalents, ending balance
|
$
|
31,948,886
|
$
|
19,190,930
|
12,757,956
|
66.5
|
%
|
31.1
|
Rule 13a-14(a)/ 15d-14(a) Certification of Chief Executive Officer
|
|
|
31.2
|
Rule 13a-14(a)/ 15d-14(a) Certification of Chief Financial Officer
|
|
|
32
|
Section 1350 Certification of Chief Executive Officer and Chief Financial Officer
|
|
|
101.INS
|
XBRL Instance Document.
|
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document.
|
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document.
|
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
Date: November 13, 2018
|
Date: November 13, 2018
|
By: /s/ Chuanmin Li
Chuanmin Li, Chief Financial Officer (Principal Financial Officer)
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
November 13, 2018
|
By: /s/Yan Tinghe
|
Tinghe Yan, Chief Executive Officer (Principal Executive Officer)
|
|
November 13, 2018
|
By: /s/Chuanmin Li
|
Chuanmin Li, Chief Financial Officer (Principal Financial Officer)
|
Document and Entity Information - shares |
6 Months Ended | |
---|---|---|
Sep. 30, 2018 |
Nov. 13, 2018 |
|
Details | ||
Registrant Name | SPRING PHARMACEUTICAL GROUP, INC. | |
Registrant CIK | 0000847464 | |
SEC Form | 10-Q | |
Period End date | Sep. 30, 2018 | |
Fiscal Year End | --03-31 | |
Trading Symbol | cyig | |
Tax Identification Number (TIN) | 300781441 | |
Number of common stock shares outstanding | 29,839,168 | |
Filer Category | Non-accelerated Filer | |
Current with reporting | Yes | |
Small Business | true | |
Emerging Growth Company | false | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q2 | |
Entity Incorporation, State Country Name | Delaware |
Consolidated Balance Sheets - Parenthetical - $ / shares |
Sep. 30, 2018 |
Mar. 31, 2018 |
---|---|---|
Details | ||
Preferred Stock, Par or Stated Value Per Share | $ 500 | $ 500 |
Preferred Stock, Shares Authorized | 45 | 45 |
Preferred Stock, Shares Issued | 45 | 45 |
Preferred Stock, Shares Outstanding | 45 | 45 |
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 100,000,000 | 100,000,000 |
Common Stock, Shares, Issued | 29,839,168 | 29,789,168 |
Common Stock, Shares, Outstanding | 29,839,168 | 29,789,168 |
Consolidated Statement of Operations - USD ($) |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2018 |
Sep. 30, 2017 |
Sep. 30, 2018 |
Sep. 30, 2017 |
|
Details | ||||
Sales | $ 18,684,939 | $ 13,866,784 | $ 39,573,786 | $ 31,001,649 |
Cost of Goods Sold | 10,619,845 | 8,811,390 | 22,584,545 | 19,098,538 |
Gross profit | 8,065,094 | 5,055,394 | 16,989,241 | 11,903,111 |
Operating expenses: | ||||
Selling expenses | 1,312,878 | 1,082,147 | 2,704,481 | 2,318,439 |
General and administrative expenses | 1,110,995 | 868,258 | 2,192,044 | 1,776,663 |
Research and development expenses | 68,424 | 62,033 | 391,157 | 126,411 |
Total operating expenses | 2,492,297 | 2,012,438 | 5,287,682 | 4,221,513 |
Income from operations | 5,572,797 | 3,042,956 | 11,701,559 | 7,681,598 |
Gain on disposal of acer truncatum bunge plants | 0 | 0 | 0 | 573,092 |
Interest income | 34,972 | 31,199 | 75,045 | 56,302 |
Income before income tax provision | 5,607,769 | 3,074,155 | 11,776,604 | 8,310,992 |
Income tax provision | 1,401,942 | 768,539 | 2,944,151 | 2,077,748 |
Net Income (Loss) | 4,205,827 | 2,305,616 | 8,832,453 | 6,233,244 |
Net income attributable to noncontrolling interest | 126,175 | 69,168 | 264,974 | 186,997 |
Net income attributable to the Company | 4,079,652 | 2,236,448 | 8,567,479 | 6,046,247 |
Other comprehensive income (loss): | ||||
Foreign currency translation adjustment | (4,125,116) | 1,908,799 | (9,662,478) | 3,564,300 |
Comprehensive income (loss) | 80,711 | 4,214,415 | (830,025) | 9,797,544 |
Comprehensive income (loss) attributable to noncontrolling interest | 2,422 | 126,432 | (24,900) | 292,747 |
Comprehensive income (loss) attributable to the Company | $ 78,289 | $ 4,087,983 | $ (805,125) | $ 9,504,797 |
Basic and diluted net loss per common share | $ 0.14 | $ 0.08 | $ 0.29 | $ 0.20 |
Basic and diluted weighted-average common shares outstanding | 29,839,168 | 29,789,168 | 29,821,682 | 29,789,168 |
Consolidated Statement of Operations - Parenthetical - USD ($) |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2018 |
Sep. 30, 2017 |
Sep. 30, 2018 |
Sep. 30, 2017 |
|
Details | ||||
Related parties amount in cost of sales | $ 3,785,996 | $ 3,020,708 | $ 8,176,320 | $ 7,309,643 |
Note 1 - Organization and Principal Activities |
6 Months Ended |
---|---|
Sep. 30, 2018 | |
Notes | |
Note 1 - Organization and Principal Activities | NOTE 1 - ORGANIZATION AND PRINCIPAL ACTIVITIES
On August 28, 2018, China YCT International Group, Inc. filed a Certificate of Amendment to its Articles of Incorporation with the State of Delaware to change its corporate name from China YCT International Group, Inc. to Spring Pharmaceutical Group, Inc. (Spring Pharmaceutical). The name change was effective as of the filing of the Certificate of Amendment with the State of Delaware.
Spring Pharmaceutical, through its 100% owned subsidiary Landway Nano Bio-Tech, Inc. ("Landway Nano"), incorporated in Delaware, owns 97% of Shandong Spring Pharmaceutical Co., Ltd. ("Shandong Spring"), incorporated in the People's Republic of China ("PRC"). Spring Pharmaceutical and its subsidiaries are collectively referred to as the Company". The Company, through its 97% owned subsidiary, Shandong Spring, is engaged in the business of (i) distributing health care supplement products, (ii) developing, manufacturing, and selling Huoliyuan capsules, a prescription medicine, and (iii) developing the acer truncatum bunge planting bases and selling acer truncatum seed oil in the PRC. Acer truncatum bunge plants are a species of maple tree. |
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies |
6 Months Ended | ||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||
Notes | |||||||||||||||||||||||||||||||||
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies | NOTE 2 BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation
The unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the Securities and Exchange Commission. In the opinion of management, the unaudited financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the financial position as of September 30, 2018 and the results of operations and cash flows for the periods ended September 30, 2018 and 2017. The financial data and other information disclosed in these notes to the interim financial statements related to these periods are unaudited. The results for the three and six months ended September 30, 2018 are not necessarily indicative of the results to be expected for any subsequent periods or for the entire year ending March 31, 2019. The balance sheet on March 31, 2018 has been derived from the audited financial statements at that date.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the Securities and Exchange Commission's rules and regulations. These unaudited financial statements should be read in conjunction with our audited financial statements and notes thereto for the year ended March 31, 2018 as included in our Annual Report on Form 10-K.
Principles of consolidation
The consolidated financial statements include the financial statements of Spring Pharmaceutical, Landway Nano and its 97% owned subsidiary, Shandong Spring. All inter-company transactions and balances are eliminated in consolidation.
Use of estimates
The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Significant accounting estimates reflected in the Company's consolidated financial statements include: the valuation of inventory, the estimated useful lives and impairment of property, equipment, intangible assets, and the valuation of deferred tax assets.
Foreign currency translation
The accounts of the Company's Chinese subsidiary are maintained in RMB and the accounts of the U.S. companies are maintained in USD. The accounts of the Chinese subsidiary were translated into USD in accordance with Accounting Standards Codification ("ASC") Topic 830 "Foreign Currency Matters". According to Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date; stockholders' equity is translated at historical rates and statement of comprehensive income items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, "Comprehensive Income." Gains and losses resulting from the foreign currency transactions are reflected in the statements of comprehensive income (loss).
The following exchange rates were used to translate the amounts from RMB into United States dollars ("USD$") for the respective periods:
Recent accounting pronouncements
The Company's management has evaluated all the recently issued accounting pronouncements during the quarter ended September 30, 2018 and does not believe that they will have a material effect on the Company's consolidated financial position and results of operations. |
Note 3 - Inventories |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 3 - Inventories | NOTE 3 - INVENTORIES
The components of inventories were as follows:
|
Note 4 - Plant, Property, and Equipment, Net |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 4 - Plant, Property, and Equipment, Net | NOTE 4 PLANT, PROPERTY, AND EQUIPMENT, NET
The components of plant, property and equipment were as follows:
The depreciation and amortization expense for the three months ended September 30, 2018 and 2017 was $329,637 and $327,864, respectively.
The depreciation and amortization expense for the six months ended September 30, 2018 and 2017 was $682,403 and $615,112, respectively. |
Note 5 - Taxes Payable |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||
Notes | |||||||||||||||||||||||||||||||||||||||||||
Note 5 - Taxes Payable | NOTE 5 - TAXES PAYABLE
Taxes payable at September 30, 2018 and March 31, 2018 were as follows:
|
Note 6 - Income Taxes |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note 6 - Income Taxes | NOTE 6 - INCOME TAXES
Spring Pharmaceutical and Landway Nano were incorporated in the United States of America and are subject to United States federal taxation. No provisions for income taxes have been made, as there was no taxable income from U.S. operations for the three and six months ended September 30, 2018 and 2017. The Company has net loss carryforward of approximately $22,000, which will expire in 2037. The Company has set up 100% valuation allowance on deferred tax assets resulting from net operating loss incurred in the U.S.
The U.S. Tax Cuts and Jobs Act (the "Act") was enacted on December 22, 2017 and introduces significant changes to U.S. income tax law. Effective in 2018, the Tax Act reduces the U.S. statutory tax rate from 35% to 21% and creates new taxes on certain foreign-sourced earnings and certain related-party payments.
The Company's Chinese subsidiary is governed by the Income Tax Law of the PRC concerning the privately run and foreign invested enterprises, which are generally subject to tax at a statutory rate of 25% on income reported in the statutory financial statements after appropriate tax adjustments.
Dividend payments by PRC subsidiaries are limited by certain statutory regulations in the PRC. No dividends may be paid by PRC subsidiaries without first receiving prior approval from SAFE. Dividend payments are restricted to 90% of after-tax profits.
The Company had not provided deferred taxes on undistributed earnings attributable to its PRC subsidiaries as they were to be permanently reinvested. On February 22, 2008, the Ministry of Finance and State Administration of Taxation jointly issued Cai Shui 2008 Circular 1, "Circular 1." According to Article 4 of Circular 1, distributions of accumulated profits earned by foreign investment enterprises ("FIE") prior to January 1, 2008 to their foreign investors would be exempt from withholding tax ("WHT"), while distribution of the profits earned by a FIE after January 1, 2008 to its foreign investors should be subject to WHT.
Prior to the enactment of the Act, since Shandong Spring intends to reinvest its earnings to further expand its businesses in mainland China, it does not intend to declare dividends to their immediate foreign holding companies in the foreseeable future. Accordingly, the Company has not recorded any deferred taxes in relation to US tax on the cumulative amount of undistributed retained earnings since January 1, 2008. Under the "#1703. Treatment of deferred foreign income upon transition to new participation exemption system-deemed repatriation" of the Act, U.S. shareholders owning at least 10% of a foreign subsidiary generally must include income, for the subsidiary's last tax year beginning before 2018, the shareholder's pro rata share of the accumulated post-'86 historical E&P of the foreign subsidiary as of the "measurement date" to the extent such E&P has not been previously subject to U.S. tax. The Company assessed its income tax effects of the Act and concluded that it had no one-time transition tax liability on its cumulative amount of undistributed retained earnings since January 1, 2008 as the Company had enough foreign tax credits available to offset the resulting incremental tax.
The reconciliation of income tax expense at the U.S. statutory rate of 21% and 35% in 2018 and 2017, to the Company's effective tax rate is as follows:
The provisions for income taxes are summarized as follows:
|
Note 7 - Stockholders' Equity |
6 Months Ended |
---|---|
Sep. 30, 2018 | |
Notes | |
Note 7 - Stockholders' Equity | NOTE 7 - STOCKHOLDERS' EQUITY
On June 4, 2018, the Company issued 50,000 shares of common stock to a consultant for marketing consulting services, which were valued at $41,000 based on the quoted market price at issuance. |
Note 8 - Related Party Transactions and Balances |
6 Months Ended |
---|---|
Sep. 30, 2018 | |
Notes | |
Note 8 - Related Party Transactions and Balances | NOTE 8 - RELATED PARTY TRANSACTIONS AND BALANCES
Balances:
(i) Security deposit to related party:
The security deposit to related party of $1,453,657 represents the deposit paid to Shandong Yongchuntang Group Co., Ltd ("Shandong Yongchuntang") on January 4, 2017 for using the direct-sales license issued to Shandong Yongchuntang. The amount is non-interest bearing and not secured. Shandong Yongchuntang owns 3% of the equity of Shandong Spring.
(ii) Trade related balance with related party:
On September 30, 2018 and March 31, 2018, purchase deposit to related party of $1,286,166 and $1,412,864, respectively, pertains to a purchase deposit paid in respect of the purchase of healthcare products from Shandong Yongchuntang.
Transactions:
(i) Purchase from related party (See Note 9)
Contingency:
The Company is authorized by Shandong Yongchuntang to sell Shandong Yongchuntang's products using the direct-sales license issued to Shandong Yongchuntang. As a condition for using the direct-sales license, the Company needs to make 20% sales increase each year based on 95% of sales in the year 2014. If the Company cannot meet this sales target in any year from April 1, 2017 to June 30, 2020, a security deposit of approximately $1.5 million will be used as an annual fee for using the direct-sales license. There is a risk that the Company may fail to meet the sales target and may need to pay approximately $1.5 million in the subsequent years. |
Note 9 - Major Customer and Vendor |
6 Months Ended |
---|---|
Sep. 30, 2018 | |
Notes | |
Note 9 - Major Customer and Vendor | NOTE 9 - MAJOR CUSTOMERS AND VENDORS
The Company sold products through ten distributors during the three and six months ended September 30, 2018 and 2017. Sales to five distributors represented 17%, 14%, 12%, 11%, and 11% of total sales for the three months ended September 30, 2018. Sales to four distributors represented 19%, 16%, 15% and 13% of total sales for the three months ended September 30, 2017.
The Company's sales through six distributors represented 16%, 14%, 12%, 12%, 11% and 10% of total sales for the six months ended September 30, 2018. Sales to four distributors represented 17%, 17%, 13% and 13% of total sales for the six months ended September 30, 2017.
The Company sold 11 products during the three months ended September 30, 2018 and 2017, respectively. Sales of three products represented 38%, 25%, and 14% of total sales for the three months ended September 30, 2018. Sales of three products represented 50%, 10%, and 10% of total sales for the three months ended September 30, 2017. The Company sold 11 products during the six months ended September 30, 2018 and 2017, respectively. Sales of three products represented 37%, 25%, and 12% of total sales for the six months ended September 30, 2018. Sales of four products represented 43%, 14%, 10% and 10% of total sales for the six months ended September 30, 2017.
The Company purchases certain of its products from Shandong Yongchuntang, a related party, according to the purchase contract signed between the Company and Shandong Yongchuntang. Pursuant to the contract dated February 20, 2017, the Company agreed to purchase nine products from Shandong Yongchuntang at fixed prices. On February 21, 2018, the Company further renewed the purchase contract with Shandong Yongchuntang for a term of one year ending on February 25, 2019. Pursuant to this most recently renewed one-year contract, the Company continues to purchase the nine products from Shandong Yongchuntang at fixed prices without changes in any terms of the previous contract. Total purchases from Shandong Yongchuntang represented 43% and 43% of our total purchases during the three months ended September 30, 2018 and 2017, respectively. The purchases from three other vendors represented 20%, 13% and 12% of the Company's total purchases for the three months ended September 30, 2018. The purchases from three other vendors represented 20%, 17% and 10% of the Company's total purchases for the three months ended September 30, 2017.
Total purchases from Shandong Yongchuntang represented 40% and 49% of our total purchases during the six months ended September 30, 2018 and 2017, respectively. The purchases from three other vendors represented 26%, 11%, and 11% of the Company's total purchases for the six months ended September 30, 2018. The purchases from two other vendors represented 20% and 16% of the Company's total purchases for the six months ended September 30, 2017. |
Note 10 - Subsequent Events |
6 Months Ended |
---|---|
Sep. 30, 2018 | |
Notes | |
Note 10 - Subsequent Events | NOTE 10 SUBSEQUENT EVENTS
The Company has evaluated subsequent events that have occurred after the date of the balance sheet through the date of issuance of these consolidated financial statements and determined that no subsequent event requires recognition or disclosure to the consolidated financial statements. |
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Basis of Presentation (Policies) |
6 Months Ended |
---|---|
Sep. 30, 2018 | |
Policies | |
Basis of Presentation | Basis of presentation
The unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the Securities and Exchange Commission. In the opinion of management, the unaudited financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the financial position as of September 30, 2018 and the results of operations and cash flows for the periods ended September 30, 2018 and 2017. The financial data and other information disclosed in these notes to the interim financial statements related to these periods are unaudited. The results for the three and six months ended September 30, 2018 are not necessarily indicative of the results to be expected for any subsequent periods or for the entire year ending March 31, 2019. The balance sheet on March 31, 2018 has been derived from the audited financial statements at that date.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to the Securities and Exchange Commission's rules and regulations. These unaudited financial statements should be read in conjunction with our audited financial statements and notes thereto for the year ended March 31, 2018 as included in our Annual Report on Form 10-K. |
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Principles of Consolidation (Policies) |
6 Months Ended |
---|---|
Sep. 30, 2018 | |
Policies | |
Principles of Consolidation | Principles of consolidation
The consolidated financial statements include the financial statements of Spring Pharmaceutical, Landway Nano and its 97% owned subsidiary, Shandong Spring. All inter-company transactions and balances are eliminated in consolidation. |
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Use of estimates (Policies) |
6 Months Ended |
---|---|
Sep. 30, 2018 | |
Policies | |
Use of estimates | Use of estimates
The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Significant accounting estimates reflected in the Company's consolidated financial statements include: the valuation of inventory, the estimated useful lives and impairment of property, equipment, intangible assets, and the valuation of deferred tax assets. |
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Foreign Currency Translation (Policies) |
6 Months Ended | ||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||
Policies | |||||||||||||||||||||||||||||||||
Foreign Currency Translation | Foreign currency translation
The accounts of the Company's Chinese subsidiary are maintained in RMB and the accounts of the U.S. companies are maintained in USD. The accounts of the Chinese subsidiary were translated into USD in accordance with Accounting Standards Codification ("ASC") Topic 830 "Foreign Currency Matters". According to Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date; stockholders' equity is translated at historical rates and statement of comprehensive income items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, "Comprehensive Income." Gains and losses resulting from the foreign currency transactions are reflected in the statements of comprehensive income (loss).
The following exchange rates were used to translate the amounts from RMB into United States dollars ("USD$") for the respective periods:
|
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies) |
6 Months Ended |
---|---|
Sep. 30, 2018 | |
Policies | |
Recent Accounting Pronouncements | Recent accounting pronouncements
The Company's management has evaluated all the recently issued accounting pronouncements during the quarter ended September 30, 2018 and does not believe that they will have a material effect on the Company's consolidated financial position and results of operations. |
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Foreign Currency Translation: Schedule of Intercompany Foreign Currency Balances (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||
Tables/Schedules | |||||||||||||||||||||||||||||||||
Schedule of Intercompany Foreign Currency Balances |
|
Note 3 - Inventories: Schedule of Inventory (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Tables/Schedules | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Inventory |
|
Note 4 - Plant, Property, and Equipment, Net: Property, Plant and Equipment (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tables/Schedules | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment |
|
Note 5 - Taxes Payable: Schedule of Taxes Payable (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||
Tables/Schedules | |||||||||||||||||||||||||||||||||||||||||||
Schedule of Taxes Payable |
|
Note 6 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Tables) |
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tables/Schedules | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Effective Income Tax Rate Reconciliation |
|
Note 6 - Income Taxes: Schedule of Provision for Income Tax Expense (Benefit) (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||
Tables/Schedules | |||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Provision for Income Tax Expense (Benefit) |
|
Note 1 - Organization and Principal Activities (Details) |
6 Months Ended |
---|---|
Sep. 30, 2018 | |
Landway Nano | |
Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions | 100.00% |
Shandong Spring Pharmaceutical | |
Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions | 97.00% |
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies: Foreign Currency Translation: Schedule of Intercompany Foreign Currency Balances (Details) |
Sep. 30, 2018 |
Mar. 31, 2018 |
---|---|---|
Details | ||
Foreign Currency Exchange Rate, Translation | 6.8792 | 6.6369 |
Foreign Currency Exchange Rate Translation Average Rate | 6.5940 | 6.7569 |
Note 3 - Inventories: Schedule of Inventory (Details) - USD ($) |
Sep. 30, 2018 |
Mar. 31, 2018 |
---|---|---|
Details | ||
Raw Materials | $ 786,007 | $ 233,138 |
Packaging materials | 190,477 | 652,179 |
Work-in-process | 152,051 | 686,234 |
Finished goods | 818,727 | 811,831 |
Inventories | $ 1,947,262 | $ 2,383,382 |
Note 4 - Plant, Property, and Equipment, Net: Property, Plant and Equipment (Details) - USD ($) |
Sep. 30, 2018 |
Mar. 31, 2018 |
---|---|---|
Details | ||
Machinery and Equipment, Gross | $ 3,285,970 | $ 3,594,861 |
Office Equipment | 769,106 | 769,589 |
Buildings and Improvements, Gross | 12,437,555 | 13,606,722 |
Leasehold Improvements, Gross | 3,876,194 | 4,240,568 |
Property, Plant and Equipment, Gross | 20,368,825 | 22,211,740 |
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | (5,606,865) | (5,418,327) |
Plant, property, and equipment, net | $ 14,761,960 | $ 16,793,413 |
Note 4 - Plant, Property, and Equipment, Net (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2018 |
Sep. 30, 2017 |
Sep. 30, 2018 |
Sep. 30, 2017 |
|
Details | ||||
Depreciation | $ 329,637 | $ 327,864 | $ 682,403 | $ 615,112 |
Note 5 - Taxes Payable: Schedule of Taxes Payable (Details) - USD ($) |
Sep. 30, 2018 |
Mar. 31, 2018 |
---|---|---|
Details | ||
Corporate Income Tax - foreign | $ 1,411,597 | $ 519,875 |
Value-Added Tax - foreign | 610,034 | 580,429 |
Other Tax and Fees - foreign | 67,792 | 63,894 |
Taxes payable | $ 2,089,423 | $ 1,164,198 |
Note 6 - Income Taxes (Details) |
6 Months Ended |
---|---|
Sep. 30, 2018
USD ($)
| |
Details | |
Operating Loss Carryforwards | $ 22,000 |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 25.00% |
Note 6 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2018 |
Sep. 30, 2017 |
Sep. 30, 2018 |
Sep. 30, 2017 |
|
Details | ||||
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | $ 2,473,087 | $ 2,908,847 | ||
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount | 471,064 | (831,099) | ||
Income tax provision | $ 1,401,942 | $ 768,539 | $ 2,944,151 | $ 2,077,748 |
Note 6 - Income Taxes: Schedule of Provision for Income Tax Expense (Benefit) (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2018 |
Sep. 30, 2017 |
Sep. 30, 2018 |
Sep. 30, 2017 |
|
Details | ||||
Current Federal Tax Expense (Benefit) | $ 2,943,354 | $ 1,799,694 | ||
Deferred taxes | 797 | 278,054 | ||
Income tax provision | $ 1,401,942 | $ 768,539 | $ 2,944,151 | $ 2,077,748 |
Note 7 - Stockholders' Equity (Details) |
6 Months Ended |
---|---|
Sep. 30, 2018
USD ($)
shares
| |
Details | |
Stock Issued During Period, Shares, Issued for Services | shares | 50,000 |
Stock Issued During Period, Value, Issued for Services | $ | $ 41,000 |
Note 8 - Related Party Transactions and Balances (Details) - USD ($) |
Sep. 30, 2018 |
Mar. 31, 2018 |
---|---|---|
Details | ||
Security deposit to related party | $ 1,453,657 | $ 1,590,305 |
Purchase deposit to related party | $ 1,286,166 | $ 1,412,864 |
Note 9 - Major Customer and Vendor (Details) |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2018 |
Sep. 30, 2017 |
Sep. 30, 2018 |
Sep. 30, 2017 |
|
Number Of Major Distributors | The Company sold products through ten distributors | The Company sold products through ten distributors | ||
Concentration Risk, Other Risk | Sales to five distributors represented 17%, 14%, 12%, 11%, and 11% of total sales | Sales to four distributors represented 19%, 16%, 15% and 13% of total sales | sales through six distributors represented 16%, 14%, 12%, 12%, 11% and 10% of total sales | Sales to four distributors represented 17%, 17%, 13% and 13% of total sales |
Concentration Risk, Product | Sales of three products represented 38%, 25%, and 14% of total sales | Sales of three products represented 50%, 10%, and 10% of total sales | Sales of three products represented 37%, 25%, and 12% of total sales | Sales of four products represented 43%, 14%, 10% and 10% of total sales |
Shandong Yongchuntang | ||||
Concentration Risk, Supplier | 43% | 43% | 40% | 49% |
Other Vendor 1 | ||||
Concentration Risk, Supplier | 20% | 20% | 26% | 20% |
Other Vendor 2 | ||||
Concentration Risk, Supplier | 13% | 17% | 11% | 16% |
Other Vendor 3 | ||||
Concentration Risk, Supplier | 12% | 10% | 11% |
M:TK&XG_ !23"0R88HS#2Q944G?-&C2J8BN)OPRYTW/OAYOIVI"T3DI&03(1]
MC,.&0#'S!^YYGEK3$SOTON7AB=>'!'M3!&=L1;S#Y!UZ+_EZMTO9)0B-F..
M2>:8"<%0?0J1+(4X)E_HR3)]LYCA)M(W\^@W^V6![:+ -@IL/Y2X_U3B$N;V
M4Q VZZD"6\=I G'\*2X(0FR8$(UDM
/&9 @]Y$N
M-W"3J??GNA&\73A./(<1<;,1D @9LYX7X&@"S\PQB0& .YC9]4B5_+S2]8^WPKY
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M:1XC/I5?W?Q)M8NM)'O-:Q 3ZJFWB;A0]C"M;*\I0>U("QM6MQ?LG^E]8!
M?6G\!<)D2 :8AY2CP%@:ONHJM5B_38SK6=?N$"RS0V*$=![]3 G-_+?L3 [)$
MT'4$-#I#;QK,%+H?&"2WWM-EP( 9+D.1P.OC=GW7,).IV^/AHI $Y>;D/9%#
MVD00)Z]O+S]^X1Q\%*IH8DAG5D:.X[W,LBT-SM@9.%X)6/-L(.+7%TE:NHG*
M+BY&-*S$\YI*C//89 R)($T$RV(OFQ'.=5;^<9FDI.3L"%!16FN-]>TUT2-&
M&Y7!L:$T2GK&B1>GX
M4V &NZ;GD'X3NZ:G#8XHNZ:G@_X_NR"AL0U9=DU/"]C0B4P_8\0.(@6FR;H;
M6##>-<0[=DW/01TX=DU/>X,/1L>V[B:<@F)FU_2TA1,=V4U@K&C-;@)C18MV
M$TZ!&>R:GL/N)K!K>EKLH;)K>KH5$[ ;#AJRSNR:GN/B)]NE."U&L&MZNANK
M,+;MSXBQ:WH.[R>R:WI:ZXVS:WH:H3V[IJ'MRD^3QV6K+]R]A%P+4$E!5,'%[5%N)31A:[^7ZGGP9.#Q ?&03C[
MR!^:#B(I-SF$7.R+%Q5Q(+Q0#XP#X<6.Z)#7P)LNUITAE=6WFR*E'Y12"^*K
MM 49(L=\6Y 1=XE,)=G9CY;9'!G"IHUE9C@KGKQZ)F?E3K4Z;EWK"YY+$\ R
M]R,:?OLTO/KEV]7- [KZ%?[M;)5:=W%?DF\Q2'NI
MSUS:$Z/GD([)9#D19/0UI8,20I5:7$=H\^>QDX?C)15F06Q'=6DI2.:.YLX?
MKD[I5W7EBY8/W,N^Q0DXUG@M^['E%@^JE=P"F62)0YD%IJ4E19G/*ZL):%?.
MNSO%O:]#'OI$2+V.HI9Y4P>&0U66A8!W9AMW2N^?..+R7R@A6^EM0\L M\0C
M,\\%9]#TDE,-&UT6*#BTPUE;MG+6MTR0L#C3-\-DM6RP*;M,5P AC':#Z8&.
M39\K6#ZJ(['?\(93!TVY,Z>-\OQ5AKAZR>#.*HLA.YR493NJ:,%0Y9(O6!!;
MDK^4(>%(:"P3O\3R6)7>E$I+2^2C+H=MF9G.1+32SPK;@DNF80D*#C]KF86%
M]Q>K.;B)KW17^O2R#&&'7[:LY:SK.]W_*W,Y:4QO 81V_H+ $SJ*N% HN8;R
MFGNFPW%;H?Y5SZXLK.M']=9^O=W:>Y)^#;%G-RDZ[CMLE!Q_>@-F_O+UW]^0Q\?'-S18>2GG]L9/UF0^9Q)%8?S;
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MG,8!#4J)@4C'#LAY\!V6T2T))WZ5Y*L(/C-)^JJJ@U?5_7?I97>JEZ3.;E4
7%*F@2RJ$'<)&U[BKL% JO+_3*D]W*;SNOOQ 6R*%)8TP;JAR
MGJA(-YZT5) E7UIR+,6):NA!>CB"E^47*E=4U0%4 :0)*I]_\AX_,+VFH1P;$.%\D=I)";Z'PCV(E2=
MAF1@UNF!.2IH2F,+BL+=ZUKI[C71$ S/$SGCL64WH]A+X]?(ZYA1JG[4BPG3DM#^Q5M; #]%H DTM4